Related Experiment Video

Updated: Jun 28, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

[Towards customized therapy for non small cell lung cancer]

David Planchard1, Benjamin Besse

  • 1Département de médecine-oncologie thoracique, Institut Gustave-Roussy, Villejuif, France. david.planchard@igr.fr

Bulletin Du Cancer
|November 14, 2008
PubMed

Insights

Despite new treatments, non-small cell lung cancer (NSCLC) prognosis is poor. Identifying predictive biomarkers is crucial for tailoring treatments and improving patient outcomes in lung cancer research.

Area of Science:

  • Oncology
  • Translational Cancer Research
  • Molecular Biology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with limited improvement in prognosis despite advances in chemotherapy.
  • Current molecular therapies targeting pathways like epidermal growth factor (EGF) receptor and angiogenesis show heterogeneous efficacy.
  • Significant variability in treatment response necessitates personalized approaches for NSCLC patients.

Purpose of the Study:

  • To highlight the critical need for discovering novel prognostic and predictive biomarkers in NSCLC.
  • To emphasize the goal of improving patient-tailored treatment strategies based on clinical, histological, or biological markers.
  • To advance the understanding of NSCLC biology for better therapeutic outcomes.

Main Methods:

  • Review of current understanding in cancer biology and cell signaling pathways relevant to NSCLC.
  • Analysis of the development and application of molecularly-targeted therapies.
  • Discussion of the challenges in predicting treatment efficacy and patient response.

Main Results:

  • Despite targeted therapies, treatment efficacy in NSCLC remains highly variable among patients.
  • Identification of potential molecular targets, including EGF receptor and angiogenesis pathways, has advanced treatment options.
  • The heterogeneity of treatment response underscores the limitations of current therapeutic strategies.

Conclusions:

  • Discovering new biomarkers is essential for personalized medicine in NSCLC.
  • Improving patient selection for specific treatments can enhance therapeutic benefit and reduce toxicity.
  • Translational research plays a vital role in identifying biomarkers to optimize NSCLC management.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.